Icariin against neuroinflammation: emerging evidence for gut-brain axis modulation involving short-chain fatty acids, vagal signaling, and extracellular vesicles

i

This article has been updated. A Correction to this article was published on .

i

The Original Article was published on

i

The Original Article was published on

i

This article has been updated

i

This article was retracted on

i

This article has been updated

Abstract

Neuroinflammation is a central pathological process in a wide range of central nervous system disorders, yet therapeutic strategies directed solely at single inflammatory targets have shown limited efficacy. Gut–brain axis dysfunction may contribute to neuroinflammatory progression through interconnected metabolic, immune, neural, and vesicle-associated routes. Icariin, a major flavonoid glycoside from Epimedii Folium, has attracted attention because of its anti-inflammatory, neuroprotective, and microbiota-modulating properties. In this review, we summarize current evidence for the anti-neuroinflammatory effects of icariin and explicitly stratify the evidence into three levels: direct icariin-related findings, icariin-related findings without causal gut–brain validation, and mechanisms inferred from broader gut–brain axis biology. Available studies provide relatively stronger support for intestinal barrier protection, microbiota remodeling, peripheral cytokine suppression, and central inflammatory pathway regulation. In contrast, short-chain fatty acid (SCFA)-associated signaling, vagal neuroimmune communication, and extracellular vesicle (EV)-mediated cargo transfer remain plausible but incompletely validated candidate routes. We further compare icariin with its major microbial metabolites, especially icariside II and icaritin, because oral icariin may act partly through metabolite-mediated exposure rather than through robust brain penetration of the parent compound. Major limitations include insufficient causal perturbation, incomplete organ-specific pharmacokinetic data, inter-individual microbiota variability, and uncertain therapeutic time windows. Overall, icariin emerges as a promising multi-target natural product for anti-neuroinflammatory research, but the causal hierarchy and translational relevance of proposed gut–brain pathways require direct validation.

Keywords

Icariin / Neuroinflammation / Gut-brain axis / Short-chain fatty acids / Vagus nerve / Extracellular vesicles

CHANGE HISTORY

A Correction to this paper has been published:
https://doi.org

The Retraction Note was updated to reflect reception of statements of disagreement from all authors.

This article has been retracted.Please see the Retraction Notice for more detail:
https://doi.org

References

[1] Liu Y, Li H, Wang X, et al. Anti-Alzheimers molecular mechanism of icariin: insights from gut microbiota, metabolomics, and network pharmacology. J Transl Med. 2023; 21(1):277. https://doi.org/10.1186/s12967-023-04137-z.

[2] Sabry HA, Zahra MM . Icariin attenuates dopaminergic neural loss in haloperidol-induced Parkinsonism in rats via GSK-3β and tyrosine hydroxylase regulation mechanism. J Chem Neuroanat. 2024; 136:102385. https://doi.org/10.1016/j.jchemneu.2023.102385.

[3] Morais LH, Schreiber HLth, Mazmanian SK . The gut microbiota-brain axis in behaviour and brain disorders. Nat Rev Microbiol. 2021; 19(4):241-255. https://doi.org/10.1038/s41579-020-00460-0.

[4] Roy S, Saha P, Bose D, et al. Periodic heat waves-induced neuronal etiology in the elderly is mediated by gut-liver-brain axis: a transcriptome profiling approach. Sci Rep. 2024; 14(1):10555. https://doi.org/10.1038/s41598-024-60664-9.

[5] Zhang WD, Li N, Du ZR, et al. IGF-1 receptor is involved in the regulatory effects of icariin and icaritin in astrocytes under basal conditions and after an inflammatory challenge. Eur J Pharmacol. 2021; 906:174269. https://doi.org/10.1016/j.ejphar.2021.174269.

[6] Wang J, Liu Y, Wu Y, et al. Anti-inflammatory effects of icariin in the acute and chronic phases of the mouse pilocarpine model of epilepsy. Eur J Pharmacol. 2023; 960:176141. https://doi.org/10.1016/j.ejphar.2023.176141.

[7] Yu Z, Su G, Zhang L, et al. Icaritin inhibits neuroinflammation in a rat cerebral ischemia model by regulating microglial polarization through the GPER-ERK-NF-κB signaling pathway. Mol Med. 2022; 28(1):142. https://doi.org/10.1186/s10020-022-00573-7.

[8] Rahman Z, Padhy HP, Dandekar MP . Cell-free supernatant of Lactobacillus rhamnosus and Bifidobacterium breve ameliorates ischemic stroke-generated neurological deficits in rats. Probiotics Antimicrob Proteins. 2025; 17(5):3083-3099. https://doi.org/10.1007/s12602-024-10256-w.

[9] Wang X, Chen W, Yuan P, et al. RAGE acted as a new anti-inflammatory target for Icariin’s treatment against vascular dementia based on network pharmacology-directed verification. J Biomol Struct Dyn. 2024; 42(19):10189-10209. https://doi.org/10.1080/07391102.2023.2256409.

[10] Borsom EM, Keefe CR, Hirsch AH, et al. A longitudinal study of the unique gut microbiota of 3xTg-AD mice modeling key AD pathologies. Alzheimers Dement. 2021; 17(S3):e054633. https://doi.org/10.1002/alz.054633.

[11] Busayli AM, Xu W, Raffah GA, et al. Gut microbiome, neuroinflammation, and fetal alcohol spectrum disorders: insights from rodent models. Biology (Basel). 2025; 14(6):593. https://doi.org/10.3390/biology14060593.

[12] Wanyi Z, Jiao Y, Wen H, et al. Bidirectional communication of the gut-brain axis: new findings in Parkinson's disease and inflammatory bowel disease. Front Neurol. 2024; 15:1407241. https://doi.org/10.3389/fneur.2024.1407241.

[13] Angeloni C, Barbalace MC, Hrelia S . Icariin and its metabolites as potential protective phytochemicals against Alzheimer’s disease. Front Pharmacol. 2019; 10:00271. https://doi.org/10.3389/fphar.2019.00271.

[14] Lin YC, Pan YJ, Chang SM, et al. Transcranial ultrasound stimulation ameliorates dextran sulphate sodium-induced colitis and behavioural disorders by suppressing the inflammatory response in the brain. Brain Commun. 2025; 7(2):fcaf119. https://doi.org/10.1093/braincomms/fcaf119.

[15] Li T, Chen H, Xu B, et al. Deciphering the interplay between LPS/TLR4 pathways, neurotransmitter, and deltamethrin-induced depressive-like behavior: perspectives from the gut-brain axis. Pestic Biochem Physiol. 2023; 197:105697. https://doi.org/10.1016/j.pestbp.2023.105697.

[16] Liu T, Wu H, Wei J . Beyond the brain: exploring the multi-organ axes in Parkinson’s disease pathogenesis. J Adv Res. 2026; 80:451-474. https://doi.org/10.1016/j.jare.2025.05.034.

[17] Gao H, Song R, Li Y, et al. Effects of oat fiber intervention on cognitive behavior in LDLR^(-/-) mice modeling atherosclerosis by targeting the microbiome-gut-brain axis. J Agric Food Chem. 2020; 68(49):14480-14491. https://doi.org/10.1021/acs.jafc.0c05677.

[18] Khezri MR, Ghasemnejad-Berenji M . Icariin: a potential neuroprotective agent in Alzheimer’s disease and Parkinson’s disease. Neurochem Res. 2022; 47(10):2954-2962. https://doi.org/10.1007/s11064-022-03667-0.

[19] Ye T, Yuan S, Kong Y, et al. Effect of probiotic fungi against cognitive impairment in mice via regulation of the fungal microbiota-gut-brain axis. J Agric Food Chem. 2022; 70(29):9026-9038. https://doi.org/10.1021/acs.jafc.2c03142.

[20] Richards EM, Li J, Stevens BR, et al. Gut microbiome and neuroinflammation in hypertension. Circ Res. 2022; 130(3):401-417. https://doi.org/10.1161/circresaha.121.319816.

[21] Zhu J, Fu Y, Olovo CV, et al. The influence of gut microbiota on the gut-brain-kidney axis and its implications for chronic kidney disease. Front Microbiol. 2025; 16:1535356. https://doi.org/10.3389/fmicb.2025.1535356.

[22] Xu TC, Lv Y, Liu QY, et al. Long-term atorvastatin improves cognitive decline by regulating gut function in naturally ageing rats. Immun Ageing. 2022; 19(1):52. https://doi.org/10.1186/s12979-022-00311-x.

[23] Jin J, Wang H, Hua X, et al. An outline for the pharmacological effect of icariin in the nervous system. Eur J Pharmacol. 2019; 842:20-32. https://doi.org/10.1016/j.ejphar.2018.10.006.

[24] Jeong DY, Ryu MS, Yang HJ, et al. γ-PGA-rich chungkookjang, short-term fermented soybeans: prevents memory impairment by modulating brain insulin sensitivity, neuro-inflammation, and the gut-microbiome-brain axis. Foods. 2021; 10(2):221. https://doi.org/10.3390/foods10020221.

[25] Tran VTA, Lee LP, Cho H . Neuroinflammation in neurodegeneration via microbial infections. Front Immunol. 2022; 13:907804. https://doi.org/10.3389/fimmu.2022.907804.

[26] Yao WH, Tao RP, Wang K, et al. Icariin attenuates vascular endothelial dysfunction by inhibiting inflammation through GPER/Sirt1/HMGB1 signaling pathway in type 1 diabetic rats. Chin J Nat Med. 2024; 22(4):293-306. https://doi.org/10.1016/S1875-5364(24)60618-7.

[27] Sharma S, Mehan S, Khan Z, et al. Exploring the neuroprotective potential of Icariin through modulation of neural pathways in the treatment of neurological diseases. Curr Mol Med. 2025; 25(8):962-979. https://doi.org/10.2174/0115665240317650240924041923.

[28] Mythri RB, Aishwarya MRB . Biopolymers as promising vehicles for drug delivery to the brain. Drug Metab Rev. 2024; 56(1):46-61. https://doi.org/10.1080/03602532.2023.2281855.

[29] Zhang T, Dong K, Xiao L, et al. Effects of co-administration of icariin and panax notoginseng saponins on intestinal microbiota and hippocampal protein expression in a mouse model of Alzheimer’s disease. Neuropsychiatr Dis Treat. 2020; 16:2169-2179. https://doi.org/10.2147/ndt.S253972.

[30] Zhu T, Zhang F, Li H, et al. Long-term icariin treatment ameliorates cognitive deficits via CD4( + ) T cell-mediated immuno-inflammatory responses in APP/PS1 mice. Clin Interv Aging. 2019; 14:817-826. https://doi.org/10.2147/cia.S208068.

[31] Ionescu VS, Popa A, Alexandru A, et al. Dietary phytoestrogens and their metabolites as epigenetic modulators with impact on human health. Antioxidants (Basel). 2021; 10(12):1893. https://doi.org/10.3390/antiox10121893.

[32] Cao YF, He RR, Cao J, et al. Drug-drug interactions potential of icariin and its intestinal metabolites via inhibition of intestinal UDP-glucuronosyltransferases. Evid Based Complement Alternat Med. 2012; 2012:395912. https://doi.org/10.1155/2012/395912.

[33] Hu W, Si Y, Xie X, et al. Research progress on icariin promoting bone injury repair and regeneration. Pharmaceuticals (Basel). 2025; 18(8):1174. https://doi.org/10.3390/ph18081174.

[34] Ma M, Fan AY, Liu Z, et al. Baohuoside I inhibits osteoclastogenesis and protects against ovariectomy-induced bone loss. Front Pharmacol. 2022; 13:874952. https://doi.org/10.3389/fphar.2022.874952.

[35] Szabó R, Rácz CP, Dulf FV. Bioavailability improvement strategies for icariin and its derivates: A Review. Int J Mol Sci. 2022; 23(14):7519. https://doi.org/10.3390/ijms23147519.

[36] Brown ES, Bice C, Putnam WC, et al. Human safety and pharmacokinetics study of orally administered icariin: randomized, double-blind, placebo-controlled trial. Nat Prod Commun. 2019; 14(6):1934578X19856789. https://doi.org/10.1177/1934578x19856789.

[37] Mensah A, Chen Y, Asinyo BK, et al. Bioactive icariin/β-CD-IC/bacterial cellulose with enhanced biomedical potential. Nanomaterials. 2021; 11(2):387. https://doi.org/10.3390/nano11020387.

[38] Asfour HZ, Alhakamy NA, Fahmy UA, et al. Zein-stabilized nanospheres as nanocarriers for boosting the aphrodisiac activity of icariin: response surface optimization and in vivo assessment. Pharmaceutics. 2022; 14(6):1279. https://doi.org/10.3390/pharmaceutics14061279.

[39] Chen Y, Wang J, Jia X, et al. Role of intestinal hydrolase in the absorption of prenylated flavonoids present in yinyanghuo. Molecules. 2011; 16(2):1336-1348. https://doi.org/10.3390/molecules16021336.

[40] Seong SH, Kim SH, Ryu JH, et al. Effects of icariin and its metabolites on GPCR regulation and MK-801-induced schizophrenia-like behaviors in mice. Molecules. 2023; 28(21):7300. https://doi.org/10.3390/molecules28217300.

[41] Wu H, Kim M, Han J . Icariin metabolism by human intestinal microflora. Molecules. 2016; 21(9):1158. https://doi.org/10.3390/molecules21091158.

[42] Cheng T, Zhang Y, Zhang T, et al. Comparative pharmacokinetics study of icariin and icariside II in rats. Molecules. 2015; 20(12):21274-21286. https://doi.org/10.3390/molecules201219763.

[43] Li N, Yuan M, Che J . Development and validation of UPLC-MS/MS method for icariin and its metabolites in mouse urine. Front Pharmacol. 2024; 15:1389754. https://doi.org/10.3389/fphar.2024.1389754.

[44] Chen G, Cao Z, Shi Z, et al. Microbiome analysis combined with targeted metabolomics reveal immunological anti-tumor activity of icariside I in a melanoma mouse model. Biomed Pharmacother. 2021; 140:111542. https://doi.org/10.1016/j.biopha.2021.111542.

[45] Xu S, Yu J, Zhan J, et al. Pharmacokinetics, tissue distribution, and metabolism study of icariin in rat. Biomed Res Int . 2017; 2017:4684962. https://doi.org/10.1155/2017/4684962.

[46] Ouyang X, Ma Q, Zhou C, et al. Natural bioactive products in the regulation of bone metabolism and regeneration. Front Pharmacol. 2025; 16:1683279. https://doi.org/10.3389/fphar.2025.1683279.

[47] Zhang B, Chen X, Zhang R, et al. Metabolite profiling, pharmacokinetics, and in vitro glucuronidation of icaritin in rats by ultra-performance liquid chromatography coupled with mass spectrometry. J Anal Methods Chem. 2017; 2017(1):1073607. https://doi.org/10.1155/2017/1073607.

[48] Zhou J, Chen Y, Wang Y, et al. A comparative study on the metabolism of epimedium koreanum nakai-prenylated flavonoids in rats by an intestinal enzyme (lactase phlorizin hydrolase) and intestinal flora. Molecules. 2014; 19(1):177-203. https://doi.org/10.3390/molecules19010177.

[49] Wang G, Yan F, Wang Y, et al. Visual sensing of β-glucosidase from intestinal fungus in the generation of cytotoxic icarisid II. Front Chem. 2022; 10:919624. https://doi.org/10.3389/fchem.2022.919624.

[50] Zhang B, Wang G, He J, et al. Icariin attenuates neuroinflammation and exerts dopamine neuroprotection via an Nrf2-dependent manner. J Neuroinflammation. 2019; 16(1):92. https://doi.org/10.1186/s12974-019-1472-x.

[51] Wang M, Yang X, Zhou Q, et al. Neuroprotective mechanism of icariin on hypoxic ischemic brain damage in neonatal mice. Oxid Med Cell Longev. 2022; 2022:1330928. https://doi.org/10.1155/2022/1330928.

[52] Li W, Liu E, Zhou Y, et al. Therapeutic potential of natural products in ischemic stroke: targeting angiogenesis. Front Pharmacol. 2025; 16:1579172. https://doi.org/10.3389/fphar.2025.1579172.

[53] Niu P, Zhang Y, Wang B, et al. Modulation of neuroinflammation by natural plant compounds: a promising approach for ischemic stroke. Front Pharmacol. 2025; 16:1603417. https://doi.org/10.3389/fphar.2025.1603417.

[54] An HM, Li MN, Yang H, et al. A validated UHPLC-MS/MS method for pharmacokinetic and brain distribution studies of twenty constituents in rat after oral administration of Jia-Wei-Qi-Fu-Yin. J Pharm Biomed Anal. 2021; 202:114140. https://doi.org/10.1016/j.jpba.2021.114140.

[55] Li XA, HO YS, Chen L, et al. The protective effects of icariin against the homocysteine-induced neurotoxicity in the primary embryonic cultures of rat cortical neurons. Molecules. 2016; 21(11):1557. https://doi.org/10.3390/molecules21111557.

[56] Guo Y, Cai Y, Zhang X . Icariin ameliorates the cognitive function in an epilepsy neonatal rat model by blocking the GluR2/ERK I/II pathway. Folia Neuropathol. 2020; 58(3):245-252. https://doi.org/10.5114/fn.2020.100067.

[57] Li LR, Sethi G, Zhang X, et al. The neuroprotective effects of icariin on ageing, various neurological, neuropsychiatric disorders, and brain injury induced by radiation exposure. Aging (Albany NY). 2022; 14(3):1562-1588. https://doi.org/10.18632/aging.203893.

[58] Zeng NX, Li HZ, Wang HZ, et al. Exploration of the mechanism by which icariin modulates hippocampal neurogenesis in a rat model of depression. Neural Regen Res. 2022; 17(3):632-642. https://doi.org/10.4103/1673-5374.320993.

[59] Fehsel K. Why is iron deficiency/anemia linked to Alzheimer’s disease and its comorbidities, and how is it prevented? Biomedicines. 2023; 11(9):2421. https://doi.org/10.3390/biomedicines11092421.

[60] Skapetze L, Owino S, Lo EH, et al. Rhythms in barriers and fluids: Circadian clock regulation in the aging neurovascular unit. Neurobiol Dis. 2023; 181:106120. https://doi.org/10.1016/j.nbd.2023.106120.

[61] Pan P, Zhao T, Zhang J, et al. Pharmacological mechanisms and therapeutic prospects of plant metabolites from traditional chinese medicine in regulating programmed cell death in Alzheimer's disease. Front Pharmacol. 2025; 16:1605214. https://doi.org/10.3389/fphar.2025.1605214.

[62] Feng F, Li Y, Huang N, et al. Icaritin, an inhibitor of beta-site amyloid cleaving enzyme-1, inhibits secretion of amyloid precursor protein in APP-PS1-HEK293 cells by impeding the amyloidogenic pathway. PeerJ. 2019; 7:e8219. https://doi.org/10.7717/peerj.8219.

[63] Liu MB, Wang W, Gao JM, et al. Icariside II attenuates cerebral ischemia/reperfusion-induced blood-brain barrier dysfunction in rats via regulating the balance of MMP9/TIMP1. Acta Pharmacol Sin. 2020; 41(12):1547-1556. https://doi.org/10.1038/s41401-020-0409-3.

[64] Zhou J, Deng Y, Li F, et al. Icariside II attenuates lipopolysaccharide-induced neuroinflammation through inhibiting TLR4/MyD88/NF-κB pathway in rats. Biomed Pharmacother . 2019; 111:315-324. https://doi.org/10.1016/j.biopha.2018.10.201.

[65] Zheng Y, Deng Y, Gao JM, et al. Icariside II inhibits lipopolysaccharide-induced inflammation and amyloid production in rat astrocytes by regulating IKK/IκB/NF-κB/BACE1 signaling pathway. Acta Pharmacol Sin. 2020; 41(2):154-162. https://doi.org/10.1038/s41401-019-0300-2.

[66] Xie Q, Li H, Lu D, et al. Neuroprotective effect for cerebral ischemia by natural products: a review. Front Pharmacol. 2021; 12:607412. https://doi.org/10.3389/fphar.2021.607412.

[67] Liu W, Li X, Li N, et al. UPLC-MS/MS method for icariin and metabolites in whole blood of C57 mice: development, validation, and pharmacokinetics study. Front Pharmacol. 2023; 14:1195525. https://doi.org/10.3389/fphar.2023.1195525.

[68] Wang YQ, Wang LM, Han LF, et al. A promising strategy of brain targeted delivery for the treatment of Parkinson's disease: cyclodextrin supramolecular inclusion complex based thermosensitive gel. J Pharm Anal. 2025; 15(5):101102. https://doi.org/10.1016/j.jpha.2024.101102.

[69] Wang J, Kong L, Guo RB, et al. Multifunctional icariin and tanshinone IIA co-delivery liposomes with potential application for Alzheimer's disease. Drug Deliv. 2022; 29(1):1648-1662. https://doi.org/10.1080/10717544.2022.2072543.

[70] Chen M, Wu J, Luo Q, et al. The anticancer properties of herba epimedii and its main bioactive componentsicariin and icariside II. Nutrients. 2016; 8(9):563. https://doi.org/10.3390/nu8090563.

[71] Luo P, An Y, He J, et al. Icaritin with autophagy/mitophagy inhibitors synergistically enhances anticancer efficacy and apoptotic effects through PINK1/Parkin-mediated mitophagy in hepatocellular carcinoma. Cancer Lett. 2024; 587:216621. https://doi.org/10.1016/j.canlet.2024.216621.

[72] Tan HL, Chan KG, Pusparajah P, et al. Anti-cancer properties of the naturally occurring aphrodisiacs: icariin and its derivatives. Front Pharmacol. 2016; 7:00191. https://doi.org/10.3389/fphar.2016.00191.

[73] Kamal NH, Heikal LA, Helmy MW, et al. Bromelain-functionalized omega-3 nanocarriers for targeted icariin delivery: a multifunctional shield for cardiac repair in doxorubicin-induced injury. J Mater Sci Mater Med. 2025; 36(1):115. https://doi.org/10.1007/s10856-025-06915-1.

[74] Liu FY, Ding DN, Wang YR, et al. Icariin as a potential anticancer agent: a review of its biological effects on various cancers. Front Pharmacol. 2023; 14:1216363. https://doi.org/10.3389/fphar.2023.1216363.

[75] Luo P, Chen J, An Y, et al. Icaritin ameliorates cisplatin-induced mitochondrial metabolic dysfunction-associated nephrotoxicity and synergistically potentiates its antitumor efficacy. Adv Sci (Weinh). 2026; 13(7):e06712. https://doi.org/10.1002/advs.202506712.

[76] He J, Zhuang L, Lei Y, et al. Clinical efficacy and safety of icaritin in patients with hepatocellular carcinoma: a real-world study. Front Pharmacol. 2026; 17:1677794. https://doi.org/10.3389/fphar.2026.1677794.

[77] Mi J, Yang Y, Zhu X, et al. Osteogenic action of the natural plant material icariin and its potential use in biomedical tissue engineering. Am J Transl Res. 2025; 17(8):5814-5828. https://doi.org/10.62347/ltgz9375.

[78] Goyal K, Afzal M, Babu MA, et al. Icariin as a therapeutic agent in breast cancer: modulating apoptosis and suppressing proliferation. J Complement Integr Med. 2025; 22(3):417-426. https://doi.org/10.1515/jcim-2024-0405.

[79] Ma X, Kim JK, Shin YJ, et al. Lipopolysaccharide-producing Veillonella infantium and Escherichia fergusonii cause vagus nerve-mediated cognitive impairment in mice. Brain Behav Immun . 2024; 118:136-148. https://doi.org/10.1016/j.bbi.2024.02.031.

[80] Zhao Z, Ning J, Bao XQ, et al. Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis. Microbiome. 2021; 9(1):226. https://doi.org/10.1186/s40168-021-01107-9.

[81] Luo YX, Yang LL, Yao XQ . Gut microbiota-host lipid crosstalk in Alzheimer's disease: implications for disease progression and therapeutics. Mol Neurodegener. 2024; 19(1):35. https://doi.org/10.1186/s13024-024-00720-0.

[82] Ding Y, Yu B, Zhou S, et al. Improvement of solubility and pharmacokinetic profile of hepatoprotector icariin through complexation with HP-γ-cyclodextrin. Front Pharmacol. 2023; 14:1138686. https://doi.org/10.3389/fphar.2023.1138686.

[83] Oyovwi MO, Udi OA . The gut-brain axis and neuroinflammation in traumatic brain injury. Mol Neurobiol. 2025; 62(4):4576-4590. https://doi.org/10.1007/s12035-024-04585-8.

[84] Xie P, Ma Z, Yang X, et al. The regulatory effects and mechanisms of plant food-derived bioactive components on gut barrier function and intestinal homeostasis: a comprehensive review. Crit Rev Food Sci Nutr. 2025; 65(31):7810-7833. https://doi.org/10.1080/10408398.2025.2481983.

[85] Taherkhani S, Ahmadi P, Nasiraie LR, et al. Flavonoids and the gut microbiome: a powerful duo for brain health. Crit Rev Food Sci Nutr. 2025; 65(28):6029-6044. https://doi.org/10.1080/10408398.2024.2435593.

[86] Baky MH, Elshahed M, Wessjohann L, et al. Interactions between dietary flavonoids and the gut microbiome: a comprehensive review. Br J Nutr. 2022; 128(4):577-591. https://doi.org/10.1017/s0007114521003627.

[87] Lin CH, Chen CC, Chiang HL, et al. Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson's disease. J Neuroinflammation. 2019; 16(1):129. https://doi.org/10.1186/s12974-019-1528-y.

[88] Wei H, Yu C, Zhang C, et al. Butyrate ameliorates chronic alcoholic central nervous damage by suppressing microglia-mediated neuroinflammation and modulating the microbiome-gut-brain axis. Biomed Pharmacother. 2023; 160:114308. https://doi.org/10.1016/j.biopha.2023.114308.

[89] Skawratananond S, McCrea GE, Lie P, et al. The synergistic interplay between vitamin A, dietary fiber, and the microbiota-gut-brain axis: a potential mechanism for preventing Alzheimer's disease. Am J Physiol Gastrointest Liver Physiol. 2025; 329(3):G484-g499. https://doi.org/10.1152/ajpgi.00097.2025.

[90] Holcomb M, Marshall AG, Flinn H, et al. Probiotic treatment induces sex-dependent neuroprotection and gut microbiome shifts after traumatic brain injury. J Neuroinflammation. 2025; 22(1):114. https://doi.org/10.1186/s12974-025-03419-1.

[91] Mao Z, Hui H, Zhao X, et al. Protective effects of dioscin against Parkinson's disease via regulating bile acid metabolism through remodeling gut microbiome/GLP-1 signaling. J Pharm Anal. 2023; 13(10):1153-1167. https://doi.org/10.1016/j.jpha.2023.06.007.

[92] Salinas E, Reyes-Pavón D, Cortes-Perez NG, et al. Bioactive compounds in food as a current therapeutic approach to maintain a healthy intestinal epithelium. Microorganisms. 2021; 9(8):1634. https://doi.org/10.3390/microorganisms9081634.

[93] Tang W, Chen D, Yu B, et al. Capsulized faecal microbiota transplantation ameliorates post-weaning diarrhoea by modulating the gut microbiota in piglets. Vet Res. 2020; 51(1):55. https://doi.org/10.1186/s13567-020-00779-9.

[94] Wang X, Chen Z, Geng B, et al. The bidirectional signal communication of microbiota-gut-brain axis in hypertension. Int J Hypertens. 2021; 2021:8174789. https://doi.org/10.1155/2021/8174789.

[95] Faraji N, Payami B, Ebadpour N, et al. Vagus nerve stimulation and gut microbiota interactions: a novel therapeutic avenue for neuropsychiatric disorders. Neurosci Biobehav Rev. 2025; 169:105990. https://doi.org/10.1016/j.neubiorev.2024.105990.

[96] Vilela C, Araújo B, Soares-Guedes C, et al. From the gut to the brain: is microbiota a new paradigm in Parkinson's disease treatment? Cells. 2024; 13(9):770. https://doi.org/10.3390/cells13090770.

[97] Naqvi S, Asar TO, Kumar V, et al. A cross-talk between gut microbiome, salt and hypertension. Biomed Pharmacother. 2021; 134:111156. https://doi.org/10.1016/j.biopha.2020.111156.

[98] Claudino Dos Santos JC, Oliveira LF, Noleto FM, et al. Gut-microbiome-brain axis: the crosstalk between the vagus nerve, alpha-synuclein and the brain in Parkinson's disease. Neural Regen Res. 2023; 18(12):2611-2614. https://doi.org/10.4103/1673-5374.373673.

[99] Bostick JW, Schonhoff AM, Mazmanian SK . Gut microbiome-mediated regulation of neuroinflammation. Curr Opin Immunol. 2022; 76:102177. https://doi.org/10.1016/j.coi.2022.102177.

[100] Zhang Y, Xie B, Chen X, et al. A key role of gut microbiota-vagus nerve/spleen axis in sleep deprivation-mediated aggravation of systemic inflammation after LPS administration. Life Sci. 2021; 265:118736. https://doi.org/10.1016/j.lfs.2020.118736.

[101] Wei Y, Mao J, Tang W, et al. Targeting Catenibacterium mitsuokai with icariin modulates gut microbiota and improves hepatic lipid metabolism in intrauterine growth restriction. ISME J. 2025; 19(1):wraf141. https://doi.org/10.1093/ismejo/wraf141.

[102] Li X, Khan I, Xia W, et al. Icariin enhances youth-like features by attenuating the declined gut microbiota in the aged mice. Pharmacol Res. 2021; 168:105587. https://doi.org/10.1016/j.phrs.2021.105587.

[103] Li Y, Liu J, Pongkorpsakol P, et al. Relief effects of icariin on inflammation-induced decrease of tight junctions in intestinal epithelial cells. Front Pharmacol. 2022; 13:903762. https://doi.org/10.3389/fphar.2022.903762.

[104] Soh H, Park S, Lee HJ, et al. P104 icariin attenuates intestinal inflammation through inhibition of the nuclear factor-ĸB signaling. J Crohns Colitis. 2022; 16(Supplement_1):i199-i200. https://doi.org/10.1093/ecco-jcc/jjab232.232.

[105] Xiong W, Ma H, Zhang Z, et al. The protective effect of icariin and phosphorylated icariin against LPS-induced intestinal epithelial cells injury. Biomed Pharmacother. 2019; 118:109246. https://doi.org/10.1016/j.biopha.2019.109246.

[106] Chen Y, Hamidu S, Yang X, et al. Dietary supplements and natural products: an update on their clinical effectiveness and molecular mechanisms of action during accelerated biological aging. Front Genet. 2022; 13:880421. https://doi.org/10.3389/fgene.2022.880421.

[107] Li X, Zhang Y, Duan L. Microbiome-kidney metabolism provides insight into the mechanism of icariin alleviates aging in older female mice. Innov Aging. 2024; 8(Supplement_1):878-879. https://doi.org/10.1093/geroni/igae098.2840.

[108] Zhang Y, Silang Q, Wang Y, et al. Integrated gut microbiota, metabolomics, and network pharmacology to investigate the anti-Alzheimer's mechanism of tripterygium glycoside. Neuropsychiatr Dis Treat. 2025; 21:1911-1933. https://doi.org/10.2147/ndt.S537129.

[109] Li C, Tang Y, Ye Y, et al. Potential of natural flavonols and flavanones in the treatment of ulcerative colitis. Front Pharmacol. 2023; 14:1120616. https://doi.org/10.3389/fphar.2023.1120616.

[110] Zhang C, Cao Z, Lei H, et al. Discovery of a novel small molecule with efficacy in protecting against inflammation in vitro and in vivo by enhancing macrophages activation. Biomed Pharmacother. 2023; 165:115273. https://doi.org/10.1016/j.biopha.2023.115273.

[111] Liang J, Li S, Dai Y, et al. Integrating transcriptomics and gut microbiota analysis reveals the anti-Osteoporotic mechanisms of wine and oil co-processed epimedium. Faseb j. 2026; 40(2):e71319. https://doi.org/10.1096/fj.202501534RR.

[112] Wang S, Wang S, Wang X, et al. Effects of icariin on modulating gut microbiota and regulating metabolite alterations to prevent bone loss in ovariectomized rat model. Front Endocrinol (Lausanne). 2022; 13:874849. https://doi.org/10.3389/fendo.2022.874849.

[113] Dong Y, Wang L, Yang M, et al. Effect of icariin on depressive behaviour in rat pups. Evidences for its mechanism of action by integrating network pharmacology, metabolomics and gut microbiota composition. Phytomedicine. 2024; 126:155422. https://doi.org/10.1016/j.phymed.2024.155422.

[114] Song W, Ren C, Dong Y, et al. Icariin ameliorates exercise-induced acute muscle injury and inflammation by regulating the expression of NF-κB and shaping gut microbiota in mice. Int J Vitam Nutr Res . 2025; 95(6):39821. https://doi.org/10.31083/ijvnr39821.

[115] Ji J, Phang HC, Gu X, et al. A review on colorectal cancer and the role of traditional chinese herbal medicine as complementary therapy. Progress In Microbes & Molecular Biology. 2024; 7(1). https://doi.org/10.36877/pmmb.a0000451.

[116] Bano N, Khan S, Ahamad S, et al. Microglia and gut microbiota: A double-edged sword in Alzheimer's disease. Ageing Res Rev. 2024; 101:102515. https://doi.org/10.1016/j.arr.2024.102515.

[117] O'Riordan KJ, Moloney GM, Keane L, et al. The gut microbiota-immune-brain axis: therapeutic implications. Cell Rep Med. 2025; 6(3):101982. https://doi.org/10.1016/j.xcrm.2025.101982.

[118] Cui D, Li M, Liu M, et al. Synergistic effect and mechanism of monoacylglycerol lipase inhibitor and icaritin in the treatment of ulcerative colitis. Int Immunopharmacol. 2024; 142(Pt A):113155. https://doi.org/10.1016/j.intimp.2024.113155.

[119] Jiao F, Gong Z . The beneficial roles of SIRT1 in neuroinflammation-related diseases. Oxid Med Cell Longev. 2020; 2020:6782872. https://doi.org/10.1155/2020/6782872.

[120] Wu LH, Huang BR, Lai SW, et al. SIRT1 activation by minocycline on regulation of microglial polarization homeostasis. Aging (Albany NY). 2020; 12(18):17990-18007. https://doi.org/10.18632/aging.103542.

[121] Song Y, Wu Z, Zhao P . The protective effects of activating Sirt1/NF-κB pathway for neurological disorders. Rev Neurosci. 2022; 33(4):427-438. https://doi.org/10.1515/revneuro-2021-0118.

[122] Yang C, Wang W, Deng P, et al. Fibroblast growth factor 21 modulates microglial polarization that attenuates neurodegeneration in mice and cellular models of Parkinson's disease. Front Aging Neurosci. 2021; 13:778527. https://doi.org/10.3389/fnagi.2021.778527.

[123] Shi J, Zou X, Jiang K, et al. SIRT1 mediates improvement of cardiac surgery-induced postoperative cognitive dysfunction via the TLR4/NF-κB pathway. World J Biol Psychia. 2020; 21(10):757-765. https://doi.org/10.1080/15622975.2019.1656820.

[124] Shu M, Cheng W, Jia X, et al. AGEs promote atherosclerosis by increasing LDL transcytosis across endothelial cells via RAGE/NF-κB/Caveolin-1 pathway. Mol Med. 2023; 29(1):113. https://doi.org/10.1186/s10020-023-00715-5.

[125] Shen J, Gong L, Sun Y, et al. Semaphorin3C identified as mediator of neuroinflammation and microglia polarization after spinal cord injury. iScience. 2024; 27(5):109649. https://doi.org/10.1016/j.isci.2024.109649.

[126] Guangtao F, Zhenkang W, Zhantao D, et al. Icariin alleviates wear particle-induced periprosthetic osteolysis via down-regulation of the estrogen receptor α-mediated NF-κB signaling pathway in macrophages. Front Pharmacol. 2021; 12:746391. https://doi.org/10.3389/fphar.2021.746391.

[127] Fu CY, Zhong CR, Yang YT, et al. Sirt1 activator SRT2104 protects against oxygen-glucose deprivation/reoxygenation-induced injury via regulating microglia polarization by modulating Sirt1/NF-κB pathway. Brain Res. 2021; 1753:147236. https://doi.org/10.1016/j.brainres.2020.147236.

[128] Li D, Yin J, Zhang Y, et al. Panax notoginseng saponins regulate the polarization of microglia by inhibiting the hematopoietic progenitor kinase 1 signaling pathway. Neuroreport. 2025; 36(13):737-745. https://doi.org/10.1097/wnr.0000000000002196.

[129] Sun Y, Zhang C, Lei T, et al. HIV1 gp120 activates microglia via TLR2-nf-κb signaling to up-regulate inflammatory cytokine expression and induce neuropathic pain. Neuropharmacology. 2024; 260:110136. https://doi.org/10.1016/j.neuropharm.2024.110136.

[130] Duan CM, Zhang JR, Wan TF, et al. SRT2104 attenuates chronic unpredictable mild stress-induced depressive-like behaviors and imbalance between microglial M1 and M2 phenotypes in the mice. Behav Brain Res. 2020; 378:112296. https://doi.org/10.1016/j.bbr.2019.112296.

[131] Sun B, Sawant H, Borthakur A, et al. Emerging therapeutic role of gut microbial extracellular vesicles in neurological disorders. Front Neurosci. 2023; 17:1241418. https://doi.org/10.3389/fnins.2023.1241418.

[132] Li Y, Zhou C, Liu H, et al. Emerging roles of extracelluar vesicles derived from bacteria, mammalian or plant cells in the pathogenesis and clinical application of neurodegenerative diseases. Biomolecules. 2024; 14(3):312. https://doi.org/10.3390/biom14030312.

[133] Abildinova GZ, Benberin VV, Vochshenkova TA, et al. The gut-brain-metabolic axis: exploring the role of microbiota in insulin resistance and cognitive function. Front Microbiol. 2024; 15:1463958. https://doi.org/10.3389/fmicb.2024.1463958.

[134] Mottawea W, Yousuf B, Sultan S, et al. Multi-level analysis of gut microbiome extracellular vesicles-host interaction reveals a connection to gut-brain axis signaling. Microbiol Spectr. 2025; 13(2):e0136824. https://doi.org/10.1128/spectrum.01368-24.

[135] Velikic G, Maric DM, Maric DL, et al. Harnessing the stem cell niche in regenerative medicine: innovative avenue to combat neurodegenerative diseases. Int J Mol Sci. 2024; 25(2):993. https://doi.org/10.3390/ijms25020993.

[136] Bátiz LF, Castro MA, Burgos PV, et al. Exosomes as novel regulators of adult neurogenic niches. Front Cell Neurosci. 2015; 9:501. https://doi.org/10.3389/fncel.2015.00501.

[137] Park MN, Kim M, Lee S, et al. Targeting redox signaling through exosomal microRNA: insights into tumor microenvironment and precision oncology. Antioxidants (Basel). 2025; 14(5):501. https://doi.org/10.3390/antiox14050501.

[138] Wang Y, Meng X, Wang S, et al. Investigating the molecular mechanism of icariin in inhibiting liver cirrhosis carcinogenesis by regulating miR-145 based on the ROS-NLRP3 pathway. Pak J Pharm Sci. 2026; 39(4):970-978. https://doi.org/10.36721/pjps.2026.39.4.Reg.15414.1.

[139] Yan Q, Song C, Liu H, et al. Adipose-derived stem cell exosomes loaded with icariin attenuated M1 polarization of macrophages via inhibiting the TLR4/Myd88/NF-κB signaling pathway. Int Immunopharmacol. 2024; 137:112448. https://doi.org/10.1016/j.intimp.2024.112448.

[140] Mo C, Zhao J, Liang J, et al. Exosomes: A novel insight into traditional Chinese medicine. Front Pharmacol. 2022; 13:844782. https://doi.org/10.3389/fphar.2022.844782.

[141] Belelli D, Lambert JJ, Wan MLY, et al. From bugs to brain: unravelling the GABA signalling networks in the brain-gut-microbiome axis. Brain . 2025; 148(5):1479-1506. https://doi.org/10.1093/brain/awae413.

[142] Kim MH, van Noort D, Sung JH, et al. Organ-on-a-chip for studying gut-brain interaction mediated by extracellular vesicles in the gut microenvironment. Int J Mol Sci. 2021; 22(24):13513. https://doi.org/10.3390/ijms222413513.

[143] Guo Y, Chen X, Gong P, et al. The gut-organ-axis concept: advances the application of gut-on-chip technology. Int J Mol Sci. 2023; 24(4):4089. https://doi.org/10.3390/ijms24044089.

[144] Seo GM, Lee H, Kang YJ, et al. Development of in vitro model of exosome transport in microfluidic gut-brain axis-on-a-chip. Lab Chip. 2024; 24(19):4581-4593. https://doi.org/10.1039/d4lc00490f.

[145] Lee H, Seo GM, Yoo H, et al. Random metastructures for nanoscale visualization of single-exosome dynamics in a gut-brain-axis-on-a-chip. ACS Nano. 2025; 19(33):30349-30360. https://doi.org/10.1021/acsnano.5c09164.

[146] Tsai SF, Hsu PL, Chen YW, et al. High-fat diet induces depression-like phenotype via astrocyte-mediated hyperactivation of ventral hippocampal glutamatergic afferents to the nucleus accumbens. Mol Psychiatry. 2022; 27(11):4372-4384. https://doi.org/10.1038/s41380-022-01787-1.

[147] Sun P, Wang M, Li Z, et al. Eucommiae cortex polysaccharides mitigate obesogenic diet-induced cognitive and social dysfunction via modulation of gut microbiota and tryptophan metabolism. Theranostics. 2022; 12(8):3637-3655. https://doi.org/10.7150/thno.72756.

[148] Choi J, Choi H, Chung J . Icariin supplementation suppresses the markers of ferroptosis and attenuates the progression of nonalcoholic steatohepatitis in mice fed a methionine choline-deficient diet. Int J Mol Sci. 2023; 24(15):12510. https://doi.org/10.3390/ijms241512510.

[149] Lin W, Jin Y, Hu X, et al. AMPK/PGC-1α/GLUT4-mediated effect of icariin on hyperlipidemia-induced non-alcoholic fatty liver disease and lipid metabolism disorder in mice. Biochemistry (Mosc). 2021; 86(11):1407-1417. https://doi.org/10.1134/s0006297921110055.

[150] Wang W, Liu F, Xu C, et al. Lactobacillus plantarum 69-2 combined with galacto-oligosaccharides alleviates d-galactose-induced aging by regulating the AMPK/SIRT1 signaling pathway and gut microbiota in mice. J Agric Food Chem. 2021; 69(9):2745-2757. https://doi.org/10.1021/acs.jafc.0c06730.

[151] Gui Y, Zhang J, Chen L, et al. Icariin, a flavonoid with anti-cancer effects, alleviated paclitaxel-induced neuropathic pain in a SIRT1-dependent manner. Mol Pain. 2018; 14:1744806918768970. https://doi.org/10.1177/1744806918768970.

[152] Wei K, Xu Y, Zhao Z, et al. Icariin alters the expression of glucocorticoid receptor, FKBP5 and SGK1 in rat brains following exposure to chronic mild stress. Int J Mol Med. 2016; 38(1):337-344. https://doi.org/10.3892/ijmm.2016.2591.

[153] Desai TD, Wen YT, Daddam JR, et al. Long term therapeutic effects of icariin-loaded PLGA microspheres in an experimental model of optic nerve ischemia via modulation of CEBP-β/G-CSF/noncanonical NF-κB axis. Bioeng Transl Med. 2022; 7(2):e10289. https://doi.org/10.1002/btm2.10289.

[154] Guo X, Qin Y, Feng Z, et al. Investigating the anti-inflammatory effects of icariin: A combined meta-analysis and machine learning study. Heliyon. 2024; 10(15):e35307. https://doi.org/10.1016/j.heliyon.2024.e35307.

[155] Yu X, Chen J, Lu F, et al. Study on the ameliorative effect of icariin mediating NO/cGMP/PKGI signalling pathway in Alzheimer's disease. Altern Ther Health Med. 2024; 6:AT10549.

[156] Ma R, Zhou Y, Huang W, et al. Icariin maintaining TMEM119-positive microglial population improves hippocampus-associated memory in senescent mice in relation to R-3-hydroxybutyric acid metabolism. J Ethnopharmacol. 2025; 340:119287. https://doi.org/10.1016/j.jep.2024.119287.

[157] Hu Y, Ma X . Icariin treatment protects against gentamicin-induced ototoxicity via activation of the AMPK-SIRT3 pathway. Front Pharmacol. 2021; 12:620741. https://doi.org/10.3389/fphar.2021.620741.

[158] Zhang H, Zhuo S, Song D, et al. Icariin inhibits intestinal inflammation of DSS-induced colitis mice through modulating intestinal flora abundance and modulating p-p65/p65 molecule. Turk J Gastroenterol. 2021; 32(4):382-392. https://doi.org/10.5152/tjg.2021.20282.

[159] Mei Y, Li W, Wang B, et al. Gut microbiota: an emerging target connecting polycystic ovarian syndrome and insulin resistance. Front Cell Infect Microbiol. 2025; 15:1508893. https://doi.org/10.3389/fcimb.2025.1508893.

[160] Li CY, Li XY, Shen L, et al. Regulatory effects of transition metals supplementation/deficiency on the gut microbiota. Appl Microbiol Biotechnol. 2021; 105(3):1007-1015. https://doi.org/10.1007/s00253-021-11096-2.

[161] Yan F, Liu J, Chen MX, et al. Icariin ameliorates memory deficits through regulating brain insulin signaling and glucose transporters in 3 × Tg-AD mice. Neural Regen Res. 2023; 18(1):183-188. https://doi.org/10.4103/1673-5374.344840.

[162] Celorio M, Friess SH . Gut-brain axis in traumatic brain injury: impact on neuroinflammation. Neural Regen Res . 2022; 17(5):1007-1008. https://doi.org/10.4103/1673-5374.324839.

[163] You M, Yuan P, Li L, et al. HIF-1 signalling pathway was identified as a potential new pathway for icariin's treatment against Alzheimer’s disease based on preclinical evidence and bioinformatics. Front Pharmacol. 2022; 13:1066819. https://doi.org/10.3389/fphar.2022.1066819.

[164] Li T, Yang Y, Yang F, et al. Organoids and organoids-on-chip in traditional chinese medicine research: applications, advantages, and future prospects. Cell Biol Int. 2025; 49(10):1233-1244. https://doi.org/10.1002/cbin.70067.

[165] Zhou Q, Chen T, Wang X, et al. Role of gut microbiota in neuroinflammation: a focus on perioperative neurocognitive disorders. Front Cell Infect Microbiol. 2025; 15:1582909. https://doi.org/10.3389/fcimb.2025.1582909.

[166] Song WS, Hung TH, Liu SH, et al. Neuroprotection by abdominal ultrasound in lipopolysaccharide-induced systemic inflammation. Int J Mol Sci. 2023; 24(11):9329. https://doi.org/10.3390/ijms24119329.

[167] Cope EK, Borsom EM, Bolyen EK, et al. Influence of fecal microbiota transplantation on gut microbiota composition and neuroinflammation of 3xTg-AD mice. Alzheimers Dement. 2021; 17(S3):e054648. https://doi.org/10.1002/alz.054648.

[168] Rao J, Qiao Y, Xie R, et al. Fecal microbiota transplantation ameliorates stress-induced depression-like behaviors associated with the inhibition of glial and NLRP3 inflammasome in rat brain. J Psychiatr Res. 2021; 137:147-157. https://doi.org/10.1016/j.jpsychires.2021.02.057.

[169] Jia X, Chen Q, Zhang Y, et al. Multidirectional associations between the gut microbiota and Parkinson's disease, updated information from the perspectives of humoral pathway, cellular immune pathway and neuronal pathway. Front Cell Infect Microbiol. 2023; 13:1296713. https://doi.org/10.3389/fcimb.2023.1296713.

[170] Yu Y, Wang W, Zhang F . The next generation fecal microbiota transplantation: to transplant bacteria or virome. Adv Sci (Weinh). 2023; 10(35):e2301097. https://doi.org/10.1002/advs.202301097.

[171] Kelly BJ, Kwon JH, Woodworth MH . Escape velocity-the launch of microbiome therapies. J Infect Dis. 2024; 230(1):2-4. https://doi.org/10.1093/infdis/jiae099.

[172] Sahle Z, Engidaye G, Shenkute Gebreyes D, et al. Fecal microbiota transplantation and next-generation therapies: A review on targeting dysbiosis in metabolic disorders and beyond. SAGE Open Med. 2024; 12:20503121241257486. https://doi.org/10.1177/20503121241257486.

[173] Xie C, Tang H, Liu G, et al. Molecular mechanism of Epimedium in the treatment of vascular dementia based on network pharmacology and molecular docking. Front Aging Neurosci. 2022; 14:940166. https://doi.org/10.3389/fnagi.2022.940166.

[174] Di X, Wan M, Bai YN, et al. Exploring the mechanism of icariin in the treatment of depression through BDNF-TrkB pathway based on network pharmacology. Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(1):463-478. https://doi.org/10.1007/s00210-023-02615-1.

[175] Xu H, You M, Xiang X, et al. Molecular mechanism of epimedium extract against ischemic stroke based on network pharmacology and experimental validation. Oxid Med Cell Longev. 2022; 2022:3858314. https://doi.org/10.1155/2022/3858314.

[176] Chen G, Huang J, Lei H, et al. Icariside I - a novel inhibitor of the kynurenine-AhR pathway with potential for cancer therapy by blocking tumor immune escape. Biomed Pharmacother. 2022; 153:113387. https://doi.org/10.1016/j.biopha.2022.113387.

[177] Gao X, Li S, Cong C, et al. A network pharmacology approach to estimate potential targets of the active ingredients of epimedium for alleviating mild cognitive impairment and treating Alzheimer's disease. Evid Based Complement Alternat Med. 2021; 2021:2302680. https://doi.org/10.1155/2021/2302680.

[178] Yuan P, Chen W, Wang X, et al. RAGE: a potential target for epimedium's anti-neuroinflammation role in vascular dementia-insights from network pharmacology and molecular simulation. J Biomol Struct Dyn. 2024; 42(20):10856-10875. https://doi.org/10.1080/07391102.2023.2259480.

[179] Wu K, Han L, Zhao Y, et al. Deciphering the molecular mechanism underlying the effects of epimedium on osteoporosis through system bioinformatic approach. Medicine (Baltimore). 2022; 101(32):e29844. https://doi.org/10.1097/md.0000000000029844.

[180] Cui J, Lin L, Hao F, et al. Comprehensive review of the traditional uses and the potential benefits of epimedium folium. Front Pharmacol. 2024; 15:1415265. https://doi.org/10.3389/fphar.2024.1415265.

[181] Xu N, Zhou G, Li X, et al. Geographical classification of Epimedium based on HPLC fingerprint analysis combined with multi-ingredients quantitative analysis. Biomed Chromatogr. 2017; 31(5). https://doi.org/10.1002/bmc.3871.

[182] Yang X, Zheng M, Hao S, et al. Curdlan prevents the cognitive deficits induced by a high-fat diet in mice via the gut-brain axis. Front Neurosci. 2020; 14:384. https://doi.org/10.3389/fnins.2020.00384.

[183] Zhang D, Xie Q, Zhang Z, et al. Real-world evidence on the efficacy of icaritin for unresectable advanced hepatocellular carcinoma: a multicenter retrospective study. Int J Cancer. 2026; 159(10):2525-2539. https://doi.org/10.1002/ijc.70590.

[184] Lu H, Xu T, Li J, et al. Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study. Front Immunol. 2026; 17:1684486. https://doi.org/10.3389/fimmu.2026.1684486.

[185] Wang J, Du Y, Su G, et al. Dual-functional pH-sensitive nanoliposomes modified with CD47 mimicry peptide enhance icariin delivery to attenuate neuroinflammation and oxidative stress in epilepsy. Mater Today Bio. 2025; 35:102528. https://doi.org/10.1016/j.mtbio.2025.102528.

[186] Zhang R, Feng R, Wang J, et al. Gut microbiota modulation via repeated donor fecal transplantation improves motor and gastrointestinal symptoms in drug-naïve Parkinson's disease: a randomized phase 2 trial. Signal Transduct Target Ther. 2026; 11(1):94. https://doi.org/10.1038/s41392-026-02604-9.

[187] Scheperjans F, Levo R, Bosch B, et al. Fecal microbiota transplantation for treatment of Parkinson disease: a randomized clinical trial. JAMA Neurol. 2024; 81(9):925-938. https://doi.org/10.1001/jamaneurol.2024.2305.

[188] Liu XR, Li M, Hao QQ, et al. Unraveling cysteinyl leukotrienes and their receptors in inflammation through the brain-gut-lung axis. Virulence. 2025; 16(1):2502555. https://doi.org/10.1080/21505594.2025.2502555.

[189] Lim LWK . A micro review on the role of recently emerged Artificial Intelligence (AI) tools and algorithms in microbiome-gut-brain-axis associated disease therapy via psychobiotics. Precision Medication. 2025; 2(3):100039. https://doi.org/10.1016/j.prmedi.2025.100039.

[190] Andafa TW, Imoh EC, Adekanmbi SA . Artificial intelligence applied to the brain-gut axis in irritable bowel syndrome: advancing toward clinical translation. Cureus. 2026; 18(5):e109142. https://doi.org/10.7759/cureus.109142.